New England Journal of Medicine, 341, 1400 927-933 (1999)

 

More about Parkinsonism after taking Ecstasy

 

R. Andrew Sewella and Nicholas V. Cozzib



aUniversity of Massachusetts
Medical Center, Worcester, MA  91655

bEast Carolina University School of Medicine, Greenville, NC  27834


          To the Editor: Mintzer et al. hypothesized that their patient had parkinsonism as a result of a delayed neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) on his basal ganglia and noted that his condition most closely resembled nigrostriatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  We question this conclusion.  The patient’s positron-emission tomographic scan was normal, and his condition did not respond to antiparkinsonian agents, unlike MPTP-induced parkinsonism.  There is currently no evidence to suggest that MDMA damages dopaminergic neurons, and none of the thousands of animals or humans exposed to MDMA have shown evidence of parkinsonism.

          MDMA is a phenethylamine, MPTP a phenylpiperidine.  Aside from a coincidental similarity in their acronyms, they are chemically unrelated and have in common neither precursors nor intermediates.  The purity of street drugs is far from perfect, and since no chemical analysis was performed, we have no evidence that this patient ingested either MDMA or MPTP.  Samples of putative MDMA obtained and analyzed in January 1998 found that 29 of 35 pills (83 percent) contained no MDMA whatsoever,1 and more detailed analyses of street MDMA by high-performance liquid chromatography show a wide variety of non-MDMA contaminants.2  The patient probably ingested a wide variety of chemicals, any one of which might have been responsible for his parkinsonian symptoms.  Whether MPTP is the culprit is doubtful, because the metabolite MPP+ (1-methyl-4-phenylpyridinium), thought to be responsible for the parkinsonism induced by MPTP, does not appear to be present in the brain after oral administration.3

References

1.     Saunders N.  Trends in quality in January 1998.  (See: http://www.ecstasy.org/testing/analysis.html)

2.     Rothe M, Pragst F, Spiegel K, Harrach T, Fischer K, Kunkel J.  Hair concentrations and self-reported abuse history of 20 amphetamine and ecstsy users.  Forensic Sci Int 1997; 89 (1-2):111-128.

3.     Fuller RW, Hemrick-Luecke SK, Perry KW.  Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice.  Life Sci 1989; 45:2077-2083.


Return to Publications
Return to Synaptic Shenanigans


This page last modified on June 17, 2003